CJC-1295 and Ipamorelin Dosage: What Patients Should Know

CJC-1295 and ipamorelin are two peptides that clinicians sometimes prescribe together to gently support the body's own growth-hormone pulses. Protocols described in the medical literature and in compounded telehealth practice commonly use 100–300 mcg of each peptide per subcutaneous injection, once nightly on an empty stomach, cycled for 8–12 weeks. Exact dosing depends on goals, weight, labs, and prescriber judgment — these peptides should never be self-dosed.

What are CJC-1295 and ipamorelin, and why are they stacked together?

Both peptides act on the same axis — the brain-to-pituitary pathway that releases growth hormone (GH) — but they push different levers. Used together, they have been studied for producing a more natural pulse of GH than either does alone [1][2].

CJC-1295 (with and without DAC)

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), built from the modified GRF 1-29 sequence that also underlies tesamorelin-class GHRH analogs [1]. It comes in two versions. CJC-1295 no-DAC (sometimes called Mod GRF 1-29) has a short half-life of about 30 minutes, so it produces a brief GH pulse that mimics the body's natural rhythm. CJC-1295 with DAC includes a Drug Affinity Complex that extends its half-life to roughly 6–8 days, producing a steady GH elevation rather than a pulse [1].

Ipamorelin

Ipamorelin is a growth hormone secretagogue / ghrelin receptor agonist that activates the ghrelin receptor in the pituitary. Unlike older secretagogues, it is selective — in published studies it raises GH without meaningfully raising cortisol or prolactin [2][3].

Why the combination

CJC-1295 influences how much GH the pituitary makes; ipamorelin influences when it is released. Stacking them has been investigated for producing a larger, cleaner GH pulse than either peptide alone, which in turn raises insulin-like growth factor 1 (IGF-1) — the downstream hormone that drives most of GH's effects on tissue repair and body composition [2]. Benefits and side effects of this combination are both dose-related and should be evaluated together with a clinician.

What is a typical CJC-1295 / ipamorelin dose?

There is no FDA-approved label for either peptide, so 'typical' dosing comes from compounding-pharmacy protocols, clinician practice, and the published peptide literature rather than a single registration trial. The ranges below are reported in those sources — they are not a prescription and do not apply to any specific person.

Weight-based vs fixed-dose protocols

Some clinicians scale dosing by body weight (often around 1–2 mcg/kg of each peptide). Others use a fixed-dose approach — typically starting at the low end and adjusting only if response is limited and side effects are absent. Fixed dosing is more common in compounded telehealth practice because it simplifies refills, but neither approach is universal.

CJC-1295 no-DAC vs with-DAC: why the dose looks so different

CJC-1295 with DAC stays active for days, so a smaller weekly amount produces sustained GHRH signaling — and a higher risk of elevated IGF-1 if overdosed. No-DAC clears in under an hour, so it is dosed nightly to preserve a pulsatile pattern. Many clinicians prefer no-DAC paired with ipamorelin because pulsatile GH release more closely matches healthy physiology [1]. Either choice should be made by a prescriber weighing goals, labs, and side-effect risk.

How often and when should it be injected?

Daily vs twice-daily schedules

Most protocols are once daily. Some clinicians use twice-daily dosing (morning and bedtime) for people focused on recovery, but evidence for added benefit is limited and side effects (water retention, blood-sugar changes) can increase. A clinician should weigh the trade-off.

Timing: bedtime and fasted state

Bedtime, on an empty stomach is the standard recommendation. The body's largest natural GH pulse happens during early deep sleep, so the peptides are timed to reinforce that pulse [4]. Food — especially carbohydrates and fats — raises insulin and blunts GH release, so most protocols suggest waiting at least 2 hours after the last meal.

Cycle length and breaks

Cycles commonly run 8–12 weeks, followed by roughly a 4-week break, to give the pituitary time to reset receptor sensitivity. Long, uninterrupted use has not been well studied and may reduce response over time, in addition to extending exposure to dose-related side effects.

How is it reconstituted and measured?

Most compounded peptides ship as a freeze-dried (lyophilized) powder that is mixed with bacteriostatic water before the first injection. Your prescriber and the compounding pharmacy will provide the exact ratio for your specific vial — this is not something to guess at or copy from the internet. The information below is for general understanding only.

Bacteriostatic water ratios (illustrative only)

As an illustration of the math: a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2,500 mcg per mL. On a U-100 insulin syringe (100 units = 1 mL), 10 units of that solution would contain 250 mcg. Different vial sizes and concentrations change this entirely — always follow the pharmacy's written instructions for your vial, and ask your clinician if anything is unclear.

Storage and stability

Unmixed (lyophilized) vials are stable at refrigerator temperatures for the labeled shelf life. Once reconstituted, vials should be refrigerated and used within the timeframe your pharmacy specifies — commonly around 30 days for the no-DAC version. Discard per pharmacy guidance; do not extend use past the labeled period.

Does the dose change for fat loss, recovery, or longevity goals?

There is no published head-to-head trial defining a 'fat-loss dose' versus a 'recovery dose.' In clinical practice, prescribers commonly start at the low end (about 100 mcg of each) and adjust only based on response, IGF-1 levels, and side effects. People focused on body composition sometimes use the upper end of the range; people focused on sleep and recovery often stay lower. All of these uses are currently being studied and none is an FDA-approved indication.

What side effects are tied to higher doses?

Common effects

Reported side effects include injection-site redness, flushing, a brief head-rush or warmth shortly after injection, vivid dreams, mild water retention, tingling in the hands or feet, increased hunger (from the ghrelin-receptor activity of ipamorelin), and headaches [2][3]. Most are mild and dose-related, and many improve when the dose is reduced.

When to lower the dose

Persistent water retention, joint aches, numbness or tingling, elevated fasting glucose, or IGF-1 climbing above the age-adjusted reference range are all reasons a clinician may lower the dose or pause therapy. GH and IGF-1 can reduce insulin sensitivity, which is especially important for anyone with prediabetes or diabetes [5]. For more detail, see our overview of ipamorelin side effects.

Red flags — call your clinician

• Severe or one-sided headaches
• Vision changes
• Significant swelling of hands, feet, or face
• New numbness or carpal-tunnel-like symptoms
• Rapid weight gain or persistently elevated blood sugar
• Any sign of allergic reaction at the injection site

These peptides should not be used by people with active or suspected cancer, during pregnancy or breastfeeding, or in children and adolescents whose growth plates are open, except under specialist care. A clinician should also review interactions if you take insulin, oral diabetes medications, or thyroid medication.

Is CJC-1295 / ipamorelin FDA approved, and how do you get it legally?

Neither CJC-1295 nor ipamorelin is FDA-approved as a finished drug product. In the United States, they are legally available only as compounded preparations made by a licensed 503A compounding pharmacy in response to a prescription from a licensed clinician [6]. Buying peptides online without a prescription — or using vials labeled 'research use only / not for human use' — is unsafe and not legal for human use.

A legitimate path typically looks like this: a clinician reviews your goals, medical history, and labs (often including IGF-1, fasting glucose, and HbA1c), determines whether a peptide protocol is clinically appropriate, and writes a prescription that a 503A pharmacy fills. Several licensed U.S. telehealth providers offer this kind of evaluation, including Chia Health, which connects patients to U.S.-licensed clinicians and 503A pharmacies for compounded longevity peptides when clinically appropriate.

If you want background on the broader category before deciding, our overview of longevity peptides and guide to 503A compounded peptides explain how this regulatory path works. For people weighing different GHRH analogs, the tesamorelin vs CJC-1295 comparison may also be useful.

Frequently asked questions

Keep reading

Longevity Peptides

Sermorelin: How This Growth Hormone Peptide Works

Peptides

CJC-1295: the long-acting GHRH analogue — 2026 evidence-based guide

Peptides

Sermorelin: the original GH-releasing peptide — 2026 evidence-based guide